Developing a new platform to find therapies that help repair nerve damage in multiple sclerosis.
Official title: In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapies.
Funded at Artificial Axon Labs INC. · NIH-10822538 · Data updated 2026-11-12
This study is working on a new way to find medicines that can help repair the protective covering around nerves in people with multiple sclerosis, using special 3D models that mimic the damaged areas in the brain.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Artificial Axon Labs INC. NIH-funded |
| Lab location | 1 site (Topsfield, United States) |
| Project start | September 13, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $506,083 |
| NIH project number | 1R43NS135867-01 |
| Project ID | NIH-10822538 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple sclerosis who are experiencing myelin damage.
✕Less likely to help
Patients with other neurological conditions unrelated to myelin damage may not benefit from this research.
What this research studies
This research focuses on creating an innovative drug screening platform called Artificial Axons to discover therapies that can promote remyelination in patients with multiple sclerosis (MS). The approach involves using advanced 3D models that mimic the environment of MS lesions, allowing researchers to test how different compounds can stimulate the repair of myelin, which is crucial for nerve function. By overcoming the limitations of traditional 2D assays, this research aims to identify effective treatments that can restore myelin and prevent further nerve damage.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking therapies that effectively repair nerve damage in multiple sclerosis, improving patient outcomes.
How similar studies have gone: While the approach of using 3D models for drug screening is gaining traction, this specific method for remyelination therapy discovery is relatively novel and has not been extensively tested.
Where this research is happening
-
Artificial Axon Labs INC.
Topsfield, United States Active
Researchers
- Principal investigator: Jagielska, Anna — Artificial Axon Labs INC.
- Study coordinator: Jagielska, Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.